How much funding has Aphea.Bio raised?

Aphea.Bio has raised $95.7M in total funding, most recently a Series C round.

Who are Aphea.Bio's investors?

Aphea.Bio's investors include ECBF, Astanor Ventures, V-Bio Ventures, Sofinnova Partners, Agri Investment Fund, Bill & Melinda Gates Foundation.

Where is Aphea.Bio headquartered?

Aphea.Bio is headquartered in Ghent, Belgium.

What industry is Aphea.Bio in?

Aphea.Bio operates in Biotechnology, Agriculture, Agtech, Biotech.

How many employees does Aphea.Bio have?

Aphea.Bio has 51-200 employees.

Aphea.Bio

Challenge the conventional. Change the norm.

Ghent, Belgium · Founded 2016 · $95.7M raised

Headquarters: Ghent
Employees: 51–200
Founded: 2016
Business Model: B2B

Website: aphea.bio
Total Funding: $95.7M
Last Round: $70.0M Series CJul 2023
Rounds: 4

About

Aphea.Bio was founded in December 2016 by Isabel Vercauteren (CEO) and Steven Vandenabeele (CTO) as a spin-off of VIB (Flemish Institute for Biotechnology) and partner universities Ghent University and KU Leuven. Located in the biotech cluster in Ghent, Belgium, the company develops biological crop protection solutions using its proprietary APEXbio™ high-throughput R&D platform. Aphea.Bio's product pipeline includes biostimulants, biofungicides, bioherbicides, and bioinsecticides derived from natural microorganisms. Key commercial products include ACTIV by APHEA bio® (biostimulant seed treatment) and INITIΛ by Aphea.Bio™. The company secured €70 million in Series C funding led by Innovation Industries, with participation from Korys Investments, the Bill & Melinda Gates Foundation, SFPIM, and BNP Paribas Fortis. Aphea.Bio is a Certified B Corporation with a score of 94.5 and employs 50+ scientists and industry specialists.

Summary

Aphea.Bio is a Biotechnology company based in Ghent, Belgium, founded in 2016. It has raised $95.7M in total across 4 rounds, most recently a $70.0M Series C round in Jul 2023. Investors include ECBF, Astanor Ventures and V-Bio Ventures.